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Article / Clinical Case Report
ABSTRACT
Chordoma is a rare tumor. It has unique clinical, pathological and immunohistochemical characteristics. Accurate diagnosis 
is essential as the tumor shows an aggressive clinical course and requires a multimodal therapeutic approach. A case with 
wide spread distant metastatic disease that was initially thought to represent metastatic thyroid carcinoma is presented. 
Appropriate clincopathologic correlation and the histologic findings raised the possibility of poorly differentiated chordoma. 
The diagnosis was confirmed by immunohistochemistry for INI-1 and Brachyury. The approach to the diagnosis emphasizing 
the clinical and pathologic findings of this case is discussed and reviewed in the context of the published literature. 
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INTRODUCTION
Chordoma is an aggressive tumor originating 
from embryonal notochordal remnants. In adults, 
it most commonly involves the sacrococcygeal area 
whereas in children it affects mostly the skull base.1 
It shows a slight male predominance with a peak 
incidence between 50-60 years of age.2 It is quite 
rare in children and adolescents.3 Although not yet 
included as a distinct entity in the current World 
Health Organization Classification of Soft Tissue and 
Bone Tumors, poorly differentiated chordoma is a 
newly recognized subtype of chordoma that is more 
common in the pediatrics age group and shows more 
aggressive biologic behavior compared to other types 
of chordoma.4-6 A characteristic feature is the loss of 
SMARCB1-INI1 expression by immunohistochemistry. 
Although this immunohistochemical staining finding 
was previously described in a minority of chordoma 
cases, the clinical features associated with those 
cases may suggest that they probably belong to the 
poorly differentiated chordoma category.6,7 Herein, 
we present a case of poorly differentiated chordoma 
arising in the cervical spine in a thirty-year-old man 
who was recently diagnosed with papillary thyroid 
carcinoma. We report the occurrence of this tumor in 
association with other malignancies and we discuss 
the diagnostic approach, the pathologic findings and 
the differential diagnosis.
CASE REPORT
A thirty-year-old man with a history of papillary 
thyroid carcinoma with cervical lymph nodes metastasis, 
who underwent total thyroidectomy with lymph 
nodes dissection few months earlier, presented with 
progressive left shoulder and arm pain associated with 
paresthesia. No other neurological symptoms were 
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present. On physical examination, a few enlarged 
cervical lymph nodes were present. Neurological 
physical examination was normal with intact sensory 
and motor functions in both upper and lower limbs. 
Laboratory tests were normal. Serum thyroglobulin 
level was low. CT scan and MRI studies showed a left 
paraspinal mass, which was centered in the left side 
of C6 vertebral body with extension from C4 to C7. 
It was associated with a large extra-osseous soft tissue 
component. Multiple enlarged mediastinal lymph 
nodes, lung nodules and other lytic bone lesions were 
seen. The initial clinical diagnosis was compatible 
with widespread metastasis from the papillary thyroid 
carcinoma versus primary malignant nerve sheath 
tumor originating from the left cervical paraspinal 
area. An Endoscopic ultrasound guided fine needle 
aspiration of the paratracheal and subcarinal lymph 
nodes showed scattered granulomas with no sign of 
malignancy. An excisional biopsy from a lung nodule 
was subsequently performed.
Histologic examination of the lung nodule showed 
a tumor composed of sheets of epithelioid to spindle 
cells exhibiting moderate amount of eosinophilic, 
pale cytoplasm with irregular and vesicular nuclei 
(Figure 1A). Scattered non-necrotizing, well-formed 
granulomas were present (Figure 1B). Prominent 
tumor necrosis was seen. Of note, a subset of 
tumor cells showed abundant cleared cytoplasm 
with smaller nuclei (Figure 1C). An initial panel of 
immunohistochemical stains revealed the tumor cells 
to be strongly and diffusely positive for pankeratin, 
cytokeratin19 (CK19) and epithelial membrane antigen 
Figure 1. Photomicrographs of the lung nodule. A – Poorly differentiated chordoma. The tumor is composed of sheets 
of epithelioid cells with eosinophilic cytoplasm (H&E, 100X); B – Poorly-differentiated chordoma. Notice the well-formed 
granuloma and the cells with clear cytoplasm in the lower right corner (H&E, 100X); C – Poorly-differentiated chordoma. 
Focal areas show tumor cells with clear to vacuolated cytoplasm admixed with epithelioid cells (H&E 200X); D – Pankeratin 
immunohistochemical stain highlighting the lesional cells (Pankeratin immunohistochemical stain, 100X).
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(EMA) (Figure 1D). The tumor cells were negative 
for thyroid transcription factor-1 (TTF-1), Paired 
box-8 (PAX8) and thyroglobulin. The diagnosis was 
initially rendered as metastatic poorly differentiated 
carcinoma, and given the patients’ known history of 
thyroid carcinoma; a primary thyroid origin was favored 
despite the negative immunohistochemistry and the 
low level of serum thyroglobulin.
The patient subsequently developed new 
bone lesions and a new left cervical mass. Biopsy 
from the cervical mass showed essentially similar 
histomorphologic and immunohistochemical features. 
The well-formed non-necrotizing granulomas 
were also present. However, an extended panel 
of immunohistochemical stains was performed 
and showed negative staining for P63, cytokeratin 
5/6 (CK5/6), S100 and CD34. INI-1 showed loss of 
expression in the tumor cells while it was intact in 
the inflammatory cells (Figure 2A). At this point, 
the differential diagnosis was expanded to include 
tumors that show keratin expression with loss of INI-1. 
The paraspinal mass was favored to represent a primary 
tumor rather than a metastatic process. The differential 
diagnosis included epithelioid malignant peripheral 
nerve sheath tumor, metastatic epithelioid sarcoma and 
poorly-differentiated chordoma. Malignant extrarenal 
rhabdoid tumor was less likely given the age of the 
patient. No soft tissue masses were present in the upper 
or lower limbs by imaging studies to suggest metastasis 
form a soft tissue sarcoma. The histologic features 
along with the negative S100 and CD34 staining ruled 
out the diagnosis of epithelioid malignant peripheral 
nerve sheath tumor. Given the age of the patient, 
the location of the mass, the histologic features of 
a poorly-differentiated tumor with scattered clear 
to vacuolated cells and the positive staining for 
keratin, EMA and loss of INI-1; poorly differentiated 
chordoma originating from the cervical spine and 
metastasizing to the lung, bone and cervical lymph 
nodes was strongly favored. Immunohistochemical 
stain for brachyury, performed at an outside facility, 
was positive confirming the diagnosis (Figure 2B).
DISCUSSION
According to the current World Health Organization 
Classification of Soft Tissue and Bone Tumors, chordoma 
is classified into three subtypes: conventional, chondroid 
and dedifferentiated.8 The conventional subtype is 
characterized by the presence of the physaliferous cells 
that are embedded in abundant extracellular myxoid 
matrix. The chondroid subtype refers to tumors with 
a matrix that mimics hyaline cartilaginous tumors. 
The dedifferentiated chordomas shows a biphasic 
morphology; typical features of chordoma with an 
abrupt juxtaposition to a high-grade undifferentiated 
spindle cell tumor or osteosarcoma.8
Poorly differentiated chordoma is a newly 
recognized subtype of chordoma.4,5 It is an exceptional 
neoplasm with very rare case series described.2,4 These 
Figure 2. Photomicrographs of the lung nodule. A – INI-1 immunohistochemical stain in poorly differentiated 
chordoma. Notice the loss of expression in the tumor cells and the intact expression in the inflammatory cells (400X); 
B – Brachyury immunohistochemical stain in poorly differentiated chordoma (200X).
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tumors are not yet included as a distinct tumor entity 
in the World Health Organization classification of soft 
tissue and bone tumors. It is more aggressive and 
quicker developing than the conventional chordoma. 
This tumor has an increased tendency to occur in the 
skull base and cervical spine.2 Acknowledgment of this 
subtype is vital because these malignancies should be 
managed aggressively with multimodality treatment. 
Compared to other chordoma subtypes, poorly 
differentiated chordoma has a significantly decreased 
mean overall survival and is characterized by a different 
clinical and immunohistochemical phenotype; with a 
distinctive SMARCB1/INI1 nuclear expression loss.6 
Poorly-differentiated chordoma arises in children and 
adolescents much more commonly than older patients, 
mostly affecting children under five years of age, with 
a slight female predominance.1,2
The differential diagnosis of poorly-differentiated 
chordoma may be challenging. This includes metastatic 
carcinoma, epithelioid sarcoma, epithelioid malignant 
peripheral nerve sheath tumor, and in children, 
myoepithelial carcinoma and extrarenal malignant 
rhabdoid tumor. Most of these tumors essentially show 
close histomorphologic features that pose diagnostic 
challenges based on the hematoxylin and eosin stain 
alone. However, attention should always be made 
to the clinical setting and the radiologic findings in 
each case (Table 1). Immunohistochemical stains are 
invaluable for the diagnosis. Although many of these 
tumors show overlapping staining patterns (Table 2), 
brachyury is believed to be a sensitive and specific 
marker for notochordal origin.2
Clinically, poorly differentiated chordoma are 
considered more aggressive than conventional 
chordoma. PDC tends to have rapid onset of local 
recurrence and metastasis. Although conventional 
chordoma may present with distant metastasis, this 
is believed to occur late in the course of disease 
due to the indolent and slow growing nature of 
conventional chordoma. According to one study,2 
when compared to spinal conventional chordoma 
and chondroid chordoma, spinal poorly differentiated 
chordoma shows significantly decreased mean overall 
survival, decreased mean progression free survival, 
decreased mean local control time and decreased mean 
metastasis free survival (Table 3). Therefore, poorly 
differentiated chordoma should be treated aggressively 
with a multimodality therapy.
Table 1. Clinical and pathologic features of the tumors included in the differential diagnosis for poorly differ-
entiated chordoma
Tumor Clinical setting Pathology
Carcinoma Older patients. A primary site 
is often detected by imaging 
studies.
Variable morphology depending on the type of carcinoma 
and site of origin. Immunohistochemical stains often help in 
determining the site of origin.
Conventional type 
epithelioid sarcoma
Involves the distal extremities 
of young adults (median age: 
30 years), involves the skin, 
subcutis, tendons or fascia.9
Epithelioid to occasionally spindle cell proliferation with 
vesicular nuclei and small nucleoli, pseudogranulomatous 
appearance
Proximal type 
epithelioid sarcoma
Arises in the deep soft tissues 
of the pelvis and perineum. 
Older patients compared 
to conventional epithelioid 
sarcoma.
Infiltrative, multinodular sheets of epithelioid cells with 
prominent atypia, rhabdoid morphology and prominent 
nucleoli. Pseudogranulomatous appearance is not seen.
Epithelioid malignant 
peripheral nerve 
sheath tumor
Most often arises in the 
subcutaneous tissue of young 
to middle aged adults. Mostly 
in the extremities. May arise in 
association with a large nerve.
Well-circumscribed, multinodular growth pattern. Relatively 
uniform cells with abundant eosinophilic cytoplasm, vesicular 
nuclei and single prominent nucleolus. The stroma might be 
myxoid.
Extrarenal malignant 
rhabdoid tumor
Affects infants and children. 
Rapidly enlarging mass that 
involves the deep soft tissues in 
axial locations (neck, paraspinal 
areas, perineum abdominal and 
pelvic cavities).8
Sheets of tumor cells with rhabdoid morphology with 
large vesicular nuclei with prominent nucleoli. Juxtanuclear 
eosinophilic, PAS positive-diastase resistant hyaline globules 
are seen.8
Myoepithelial 
carcinoma
Predominates in the pediatric 
population. Mostly in the 
extremities.10
The tumor shows heterogeneous morphology with epithelioid 
(usually the predominant pattern), clear, spindle and/or 
plasmacytoid cells forming nests, cords or solid sheets in a 
myxoid or hyalinized stroma.
Jaber OI, Ashhab MA
5-6Autops Case Rep (São Paulo). 2019 Oct-Dec;9(4):e2019120
T h e  c u r r e n t  c a s e  s h o w s  t h e  c l a s s i c 
histomorphological and immunohistochemical 
aspects of poorly differentiated chordoma that were 
described in the literature. The negative S100 staining 
is common in poorly differentiated chordoma in 
contrast with conventional chordoma which shows 
more frequent S100 staining.2 A few peculiar features 
are present in this case. First, the presence of the 
non-necrotizing granulomas in the lung and the lymph 
node was not clearly explained. We favor that those 
are probably not related to the histologic spectrum of 
poorly-differentiated chordoma and may represent a 
separate pathologic process or less likely a reaction to 
the metastatic tumor. Second, the history of papillary 
thyroid carcinoma and the age of the patient made the 
diagnosis more challenging given the need to exclude 
metastatic papillary carcinoma, possibly undergoing 
higher grade transformation especially to poorly 
differentiated or anaplastic carcinoma. The age of the 
patient which is above the typical age of occurrence 
for poorly differentiated chordoma further added to 
the initial diagnostic thought that the tumor was more 
probably metastatic papillary carcinoma rather than 
representing a new diagnosis. Furthermore, the rare 
association of poorly differentiated chordoma with 
other malignancies can negatively impact expanding 
the differential diagnosis in similar cases especially in 
the setting of a widely metastatic tumor that is strongly 
positive for keratin. In fact, to the best of our knowledge, 
we believe that this is the first reportable case of poorly 
differentiated chordoma occurring in association with 
other malignancies. Whether the association between 
those two tumors in a short period of time has a specific 
etiologic link needs further investigations.
Poorly differentiated chordoma has distinct 
clinical features, immunohistochemical staining profile 
and prognostic implications. We reported a case of 
metastatic poorly differentiated chordoma in an adult 
man with a history of papillary thyroid carcinoma. 
These tumors should always be considered in the 
clinical setting of metastatic disease with an axial 
located mass. The poorly differentiated morphology 
along with the absence of the typical myxoid matrix 
and the physaliferous cells poses diagnostic challenges. 
However, the use of INI-1 and brachyury immunostains 
is always recommended in such cases. Recognition of 
this tumor is important as it carries worse prognosis 
and needs more aggressive therapeutic approaches.
Table 2. Immunohistochemical stains for the differential diagnosis of poorly differentiated chordoma
Tumor Keratin S100 INI-1 Brachyury
Carcinoma + - Intact* -
Epithelioid sarcoma + - Lost -
Epithelioid malignant peripheral nerve sheath tumor + + Lost in 50%.11 -
Extrarenal malignant rhabdoid tumor + +/- Lost -
Myoepithelial carcinoma + +/- Lost in 10-40%.10,11 -
Poorly differentiated chordoma + +/- Lost +
*INI-1 expression can be lost in some carcinomas including renal medullary carcinoma, a subset of myoepithelial carcinoma 
and rare carcinomas of the endometrium.12,13
Table 3. Prognostic parameters of spinal poorly differentiated chordoma compared to spinal conventional and 
chondroid chordoma2
Spinal poorly 
differentiated 
chordoma
Spinal conventional 
chordoma
Spinal chondroid 
chordoma
P value*
Mean overall survival 46 months 129 months 101 months 0.035
Mean progression 
free survival 23 months 100 months 60 months <0.0005
Mean local control 
time 31 months 121 months 63 months 0.006
Mean metastasis free 
survival 30 months 165 months 83 months <0.005
*When comparing spinal poorly differentiated chordoma with spinal conventional and chondroid chordoma.
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